Browse the evidence

Genetic deletion of Acetyl-CoA Carboxylase 2 (ACC2) protects against obesity and type 2 diabetes induced by high-fat/high-carbohydrate diets by increasing fatty acid oxidation and preventing intracellular lipid accumulation.

This research suggests that the inability to oxidize fatty acids efficiently (due to high malonyl-CoA levels from ACC2 activity) is a key driver of diet-induced obesity and insulin resistance. While this specific genetic modification is not a human intervention, it highlights that strategies enhancing fatty acid oxidation or reducing malonyl-CoA levels could be therapeutic targets for preventing obesity and type 2 diabetes in individuals consuming high-fat/high-carbohydrate diets.

In middle-aged women, short sleep duration is not significantly associated with incident diabetes; instead, long sleep duration (≥9 hours) shows a non-significant trend toward increased risk.

For middle-aged women, the link between short sleep and diabetes is not as clear-cut as it is for men. This study suggests that long sleep (≥9 hours) might be a marker for underlying health issues or risk, rather than short sleep being the primary driver. Women should focus on healthy sleep duration (7-8 hours) and consult a doctor if they consistently need very long sleep, as it may indicate other metabolic or health concerns.

Obesity causes supersaturated cholesterol bile primarily through excessive hepatic cholesterol secretion, not by a deficiency in bile acids or phospholipids.

If you are obese, your liver is likely secreting excess cholesterol into your bile, making you prone to gallstones. This is a metabolic consequence of obesity itself, not just what you eat. While weight loss reduces this risk, the underlying tendency is driven by the excess body fat altering liver secretion rates.

Aging is associated with a decline in gut microbiota diversity, a decrease in beneficial butyrate-producing bacteria, and an increase in opportunistic pathogens, correlating with increased frailty and inflammation.

As you age, your gut bacteria change, often becoming less diverse and producing fewer beneficial compounds. This is linked to frailty. Maintaining a high-fiber diet and social engagement (if in care) may help preserve microbiota diversity.

Dapagliflozin monotherapy reduces hepatocyte injury biomarkers and FGF21 levels, suggesting a disease-modifying effect on NAFLD/NASH, but this effect is negated when combined with OM-3CA.

Dapagliflozin alone (10 mg daily) significantly reduces markers of liver cell injury (such as AST, ALT, and GGT) and FGF21 in patients with Type 2 Diabetes and NAFLD, suggesting it may modify the disease. However, adding OM-3CA (4 g daily) negates this specific benefit on injury biomarkers, even though the combination is superior for reducing total liver fat.

Melatonin acts as a mitochondria-targeted antioxidant by accumulating in high concentrations within mitochondria via oligopeptide transporters (PEPT1/2), where it directly scavenges reactive oxygen species (ROS) and stimulates antioxidant enzymes (SOD, GPx) to mitigate oxidative stress and age-related decline.

Melatonin is not just a sleep hormone; it is a potent antioxidant that concentrates inside your cells' energy producers (mitochondria). This positioning allows it to neutralize damaging free radicals more effectively than many other antioxidants, potentially slowing age-related cellular decline. While the paper focuses on mechanisms, this suggests that maintaining healthy melatonin rhythms or supplementation could support long-term cellular health.

Oxidative stress accelerates telomere shortening disproportionately compared to genomic DNA due to telomeric DNA's poor repair capacity for single-strand breaks.

Telomeres are more vulnerable to oxidative damage than the rest of your DNA because they are harder to repair. Reducing oxidative stress (e.g., through diet and lifestyle) may help preserve telomere length.

Higher body mass index (BMI) and waist circumference (WC) are significantly associated with altered DNA methylation levels at specific genomic loci (including CPT1A, ABCG1, and HIF3A) in leukocytes, and these epigenetic signatures replicate across different ethnicities and tissue types, suggesting a biological link between adiposity and gene regulation.

This research confirms that carrying excess weight leaves a measurable 'epigenetic signature' on your blood cells, involving genes related to metabolism and inflammation. While the effect size of any single gene is small, the cumulative pattern is robust and replicable. Crucially, because these marks are modifiable, maintaining a healthy weight or losing weight may help normalize these epigenetic patterns, potentially reducing long-term disease risk.

DNA methylation changes at loci such as CPT1A and ABCG1 are associated not just with current BMI, but with BMI change over time, suggesting these epigenetic markers may reflect dynamic metabolic history rather than just static adiposity.

Your body's epigenetic 'record' includes your history of weight gain or loss, not just your current size. This suggests that past weight fluctuations leave a lasting biological mark. While this doesn't change immediate dietary advice, it highlights the importance of sustainable weight management to avoid negative epigenetic impacts from yo-yo dieting or prolonged obesity.

The association between obesity and DNA methylation at loci like HIF3A is not universal across all populations; specifically, HIF3A methylation associated with BMI in African Americans and European adults did not replicate in White replication cohorts (FHS/GOLDN) in this study.

Not all genetic or epigenetic markers for obesity work the same way for everyone. The HIF3A marker, often cited in research, was not found to be associated with BMI in this study's White cohorts, highlighting the need for personalized medicine approaches rather than one-size-fits-all biomarkers.

Central nervous system regulation, particularly via the hypothalamus, is essential for homeostatic control of energy balance and glucose metabolism; defective brain-peripheral crosstalk contributes to obesity and type 2 diabetes.

Understanding that your brain plays a central role in regulating hunger, energy use, and blood sugar is key. If you struggle with obesity or diabetes, it may not just be about what you eat, but how your brain processes metabolic signals. Addressing central resistance (e.g., through lifestyle changes that improve brain insulin/leptin sensitivity) is as important as peripheral factors.

Leptin resistance in obesity involves impaired transport across the blood-brain barrier and defective hypothalamic signaling (e.g., STAT3, PI3K), leading to reduced satiety and energy expenditure.

In obesity, your body produces plenty of leptin, but your brain doesn't hear it. This 'leptin resistance' means you feel hungry and store fat more easily. Improving brain sensitivity to leptin (through weight loss, exercise, and sleep) is more effective than trying to add more leptin.

Central insulin signaling regulates hepatic glucose production via the vagus nerve and hepatic IL-6/STAT3 pathway, independent of peripheral insulin levels.

Insulin doesn't just work on your muscles; it also works on your brain to tell your liver to stop making sugar. If your brain is resistant to insulin, your liver may overproduce glucose, contributing to high blood sugar. Strategies that improve overall metabolic health may help restore this central signaling.

Mitochondrial dysfunction, specifically the accumulation of somatic mtDNA mutations, causes premature aging phenotypes in mammals, whereas the associated increase in reactive oxygen species (ROS) is not the primary driver of this damage.

Focus on maintaining mitochondrial integrity through healthy lifestyle choices that support cellular repair mechanisms, rather than relying solely on antioxidant supplements to neutralize ROS. The accumulation of genetic errors in mitochondria over time is a key driver of aging, and current evidence suggests this is distinct from simple oxidative damage.

Rising obesity in developed countries is primarily driven by increased caloric intake (energy in) rather than reduced physical activity (energy out).

To manage weight in the modern developed world, focus on reducing caloric intake. The evidence suggests that increased food availability, lower food prices, and sociodemographic shifts (like urbanization and female labor force participation) have driven up calorie consumption, which is the main driver of obesity. While physical activity is important for health, it is not the primary factor driving the obesity epidemic; therefore, dietary changes are the most effective intervention for weight loss.

Plasma leptin concentrations are not affected by dietary fat content (ranging from 14% to 31% of energy) when body weight and adiposity are held constant.

If you are maintaining your current weight, changing the percentage of fat in your diet (whether you eat 14%, 23%, or 31% of calories from fat) will not change your leptin levels. Leptin is driven by how much body fat you have, not by the specific macronutrient ratio of your food, provided your weight remains stable.

Microalgae species with robust cell walls (e.g., Porphyridium, Phaeodactylum) exhibit significantly lower in vitro digestibility compared to species with simpler cell structures (e.g., Arthrospira, Chlorella vulgaris), limiting nutrient bioavailability.

If you are choosing a microalgae supplement, look for species known for high digestibility like Arthrospira (Spirulina) or Chlorella vulgaris. Species like Porphyridium or Phaeodactylum may have lower nutrient absorption due to tough cell walls. Processing methods (like breaking cell walls) can mitigate this, but raw biomass digestibility varies significantly by strain.

Population-based food fortification is the most effective and safe public health strategy to prevent micronutrient deficiency conditions, superior to individual supplementation for widespread impact.

Ensure your diet includes fortified staples like iodized salt, enriched flour, and vitamin D-fortified milk. This is the most reliable way to prevent common deficiencies like anemia, goiter, and bone issues, especially if you are in a high-risk group like pregnancy or old age.

In healthy humans, higher body fat percentage and BMI are directly correlated with increased resting muscle sympathetic nerve activity (MSNA), which in turn is correlated with increased calf vascular resistance.

Higher body fat is linked to higher sympathetic nerve activity, which increases blood vessel resistance. This physiological link helps explain why obesity is a risk factor for hypertension. While you cannot directly 'turn off' this nerve activity, understanding this link highlights why weight management is crucial for cardiovascular health, as reducing fat mass may help normalize sympathetic tone and vascular resistance.

Acute elevation of plasma insulin to levels observed in fasting overweight subjects stimulates sympathetic nerve activity in lean subjects, suggesting hyperinsulinemia contributes to sympathetic activation in obesity.

High insulin levels, even in lean individuals, can trigger increased sympathetic nerve activity. This suggests that insulin resistance and high fasting insulin levels in overweight individuals may be a key driver of the high blood pressure and vascular resistance seen in obesity. Managing insulin levels through diet and lifestyle may help reduce this sympathetic drive.

Aging is characterized by a specific redistribution of body composition involving increased total fat mass and visceral adiposity alongside decreased lean mass and bone density, which drives chronic low-grade inflammation (metaflammation) and increases the risk of age-related diseases independent of overall body weight or BMI.

As you age, your weight might stay the same, but your body composition changes: you gain fat (especially around the organs) and lose muscle and bone. This 'silent' change is more dangerous than being overweight. Do not rely on BMI. Focus on maintaining muscle mass through strength training and protein intake, and monitor visceral fat via imaging if possible, as this specific type of fat drives inflammation and disease risk.

MRI is the most advanced and accurate technique for evaluating muscle quality and detecting early fatty infiltration (sarcopenia) in aging, offering superior contrast between fat and muscle compared to CT or DXA, despite higher costs and complexity.

For the most detailed look at muscle health, especially to detect early muscle loss (sarcopenia) before it becomes obvious, MRI is the best tool. It can see fat inside muscles that other scans miss. However, due to cost and availability, it is typically reserved for research or complex cases rather than routine check-ups.

In obese women, increased adipose tissue 11β-HSD1 activity regenerates cortisol locally, contributing to central obesity and insulin resistance, while impaired hepatic conversion of cortisone to cortisol leads to compensatory HPA axis activation without raising circulating cortisol levels.

For obese women, high body fat is linked to increased activity of an enzyme (11β-HSD1) in fat tissue that converts inactive cortisone into active cortisol locally. This local excess drives insulin resistance and fat accumulation, even if blood cortisol levels appear normal. Future treatments may target this specific enzyme in fat rather than just managing stress or blood cortisol levels.

Chronic glucocorticoid excess causes central fat redistribution and metabolic syndrome features despite acute lipolytic effects, primarily through increased de novo lipogenesis and adipocyte differentiation rather than sustained systemic lipolysis.

If you are on long-term steroid medication or have high chronic cortisol levels, do not expect fat loss from stress-induced lipolysis. Instead, focus on managing insulin levels and caloric intake, as the hormonal environment promotes fat storage in the abdomen and liver through increased synthesis and cell differentiation, not just calorie burning.